Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 11;33(6):1078-1093.e12.
doi: 10.1016/j.ccell.2018.05.008.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Ewa Gogola  1 , Alexandra A Duarte  1 , Julian R de Ruiter  2 , Wouter W Wiegant  3 , Jonas A Schmid  4 , Roebi de Bruijn  2 , Dominic I James  5 , Sergi Guerrero Llobet  6 , Daniel J Vis  7 , Stefano Annunziato  1 , Bram van den Broek  8 , Marco Barazas  1 , Ariena Kersbergen  9 , Marieke van de Ven  10 , Madalena Tarsounas  11 , Donald J Ogilvie  5 , Marcel van Vugt  6 , Lodewyk F A Wessels  7 , Jirina Bartkova  12 , Irina Gromova  13 , Miguel Andújar-Sánchez  14 , Jiri Bartek  12 , Massimo Lopes  4 , Haico van Attikum  3 , Piet Borst  9 , Jos Jonkers  15 , Sven Rottenberg  16
Affiliations
Free article

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Ewa Gogola et al. Cancer Cell. .
Free article

Erratum in

  • Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
    Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S. Gogola E, et al. Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. Cancer Cell. 2019. PMID: 31185216 Free PMC article. No abstract available.

Abstract

Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, drug resistance is a clinical hurdle, and we poorly understand how cancer cells escape the deadly effects of PARPi without restoring the HR pathway. By combining genetic screens with multi-omics analysis of matched PARPi-sensitive and -resistant Brca2-mutated mouse mammary tumors, we identified loss of PAR glycohydrolase (PARG) as a major resistance mechanism. We also found the presence of PARG-negative clones in a subset of human serous ovarian and triple-negative breast cancers. PARG depletion restores PAR formation and partially rescues PARP1 signaling. Importantly, PARG inactivation exposes vulnerabilities that can be exploited therapeutically.

Keywords: BRCA1; BRCA2; PARG; PARP inhibitor; PARP1; PARylation; drug resistance; homologous recombination; replication fork.

PubMed Disclaimer

Publication types

MeSH terms

Substances